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The extracellular fibrinogen-binding protein (Efb), an immunosuppressive and anti-inflamma-
tory protein secreted by Staphylococcus aureus, has been identified as a potent inhibitor of
complement-mediated innate immunity. Efb functions by binding to and disrupting the
function of complement component 3 (C3). In a recent study, we presented a high-resolution
co-crystal structure of the complement inhibitory domain of Efb (Efb-C) bound to its cognate
domain (C3d) from human C3 and employed a series of structure/function analyses that
provided evidence for an entirely new, conformational change-based mechanism of comple-
ment inhibition. To better understand the Efb/C3 complex and its downstream effects on C3
inhibition, we investigated the solvent-accessibility and protein interface of Efb(-C)/C3d using
a method of lysine acetylation, proteolytic digestion, and mass spectrometric analysis. Lysine
modification in Efb was monitored by the mass increment of lysine-containing fragments.
Besides confirming the binding sites observed in co-crystal structure study, the in-solution
data presented here suggest additional contacting point(s) between the proteins that were not
revealed by crystallography. The results of this study demonstrate that solution-based analysis
of protein–protein interactions can provide important complementary information on the
nature of protein–protein interactions. (J Am Soc Mass Spectrom 2008, 19, 55–65) © 2008
American Society for Mass SpectrometryIn the last two decades, chemical labeling coupledwith mass spectrometry has emerged as a powerfulapproach in structural proteomics research [1]. The
availability of robust chemical modification strategies,
in combination with sensitive and accurate mass spec-
trometric techniques, has allowed the exploration of
protein structure, protein conformational dynamics,
and the determination of protein–protein interactions in
solution. The general principle behind these strategies is
that solvent-exposed residues undergo chemical modi-
fication more quickly than nonexposed residues. When
a target protein is labeled in the presence and absence of
a ligand, mass differences found by mass spectrometry
(MS) analysis will help determine the residues involved
in the contacting sites. Typically, spatial resolution is
achieved by proteolytically digesting the protein of
interest after chemical modification and analyzing the
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doi:10.1016/j.jasms.2007.10.009resulting fragments by MS. By comparing the mass of
the resultant proteolytic peptides between unmodified
and modified proteins, the location and magnitude of
label incorporation can be identified, revealing areas in
the protein of increased and decreased solvent exposure.
Implicit in these data are details regarding protein–protein
interfaces and also regions which undergo conformational
change in response to ligand.
One of the most utilized chemical labeling methods
is lysine residue modification [2–6]. Lysine residue
labeling offers many advantages for studying protein
solvent accessibility, one of which is the unique reac-
tivity of the lysine side-chain primary amine. Further-
more, proteins modified at their lysine residues do not
rapidly lose incorporated label and do not require
special handling. By virtue of these features, the analyt-
ical method used to determine the site of modification
is not time-sensitive. In the particular case of the extra-
cellular fibrinogen-binding protein (Efb1) and the C-
terminal domain of extracellular fibrinogen-binding
protein (Efb-C), the relatively large number of lysine
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56 CHEN ET AL. J Am Soc Mass Spectrom 2008, 19, 55–65residues (20 of 137 residues for Efb; 13 of 75 residues for
Efb-C) provides the opportunity for superior sequence
coverage via the lysine-labeling approach. In addition,
several of the Efb residues that comprise the complex
interface are either lysine themselves or are in the near
vicinity of lysine side-chains.
Staphylococcus aureus is the etiologic agent for a
remarkable variety of skin, soft tissue, respiratory,
bone, joint, and cardiovascular disorders [7–11]. While
many factors are thought to contribute to the ability of
S. aureus to cause a range of clinical disease, recent work
has indicated that the bacterium can bypass a compe-
tent immune response with some degree of efficiency.
To this end, S. aureus expresses multiple immunomodu-
latory proteins that target both innate and adaptive
immune responses. By facilitating the successful escape
of the microbe from the various elimination mecha-
nisms of immunity [12], the pathogen can eventually
colonize the discrete microenvironments within the
human host [12–14]. The ultimate manifestation of this
process is disseminated bacterial infection and disease.
The complement system is a central component of
innate immunity and plays a critical role in both elim-
inating invading pathogens and activating downstream
immune defense mechanisms. Numerous pathogens
have evolved sophisticated means to neutralize the
complement system, since their survival in host tissues
is predicated upon their ability to avoid complement
attack [12]. Among the complement proteins, comple-
ment component 3 (C3) is central as it can propagate the
classical, alternative and mannose-binding lectin (MBL)
pathways of complement activation [15, 16]. Several
studies have demonstrated that S. aureus infection is
associated with the activation of complement through
all three pathways [17–20], and the ensuing deposition
of C3b on the bacterial surface was found to enhance
opsonophagocytic clearance of the pathogen [21]. Sa-
kiniene et al. showed that complement depletion aggra-
vated S. aureus-induced arthritis and septicemia in a
murine model, implying a critical role of complement
system for protection against S. aureus infections [22].
Subsequently, Lee and colleagues identified a 19-kD Efb
secreted by S. aureus that can inhibit the activation of
complement and thereby suppress C3b deposition onto
sensitized surfaces [23]. In support of this, Liang and
coworkers observed that Efb contributed to bacterial
adhesion and invasion within the host [24]. Further-
more, S. aureus strains deleted for Efb were found less
virulent in a mouse model of wound healing [25].
Together, these results have strongly suggested that
Efb-mediated inhibition of complement activation is an
important determinant in S. aureus pathogenesis.
To gain insight into the mechanism of Efb function,
we recently determined the crystal structure of its
C3-inhibitory domain (denoted Efb-C) both free and
bound to its cognate C3d subdomain from human C3
[26]. These structures revealed that Efb-C adopts a
novel three helix bundle motif involved in comple-
ment regulation and provided insight into the protein–protein interaction network that targets Efb to the
surface of C3. Subsequent functional studies demon-
strated that Efb binding to C3 is required for its com-
plement inhibitory activity, and that Efb renders this
central component unable to participate in downstream
activation events by altering the solution conformation
of its native C3 precursor.
In that previous work, nearly 10% of the Efb-C
polypeptide is disordered in the crystal lattice. These
residues are therefore invisible in the refined structure
of the Efb-C/C3d complex. As a consequence, the
potential contributions of these N-terminal regions to
complement inhibition remain largely unexplored. In
this particular case, even transiently stable interactions
between Efb and C3 may be biologically relevant since
binding of Efb-C is known to effect to the solution
conformation of C3 [26]. Furthermore, proteins may
adopt conformations in solution that differ in small but
important aspects from those observed in accurately
refined crystal structures. Consequently, it can be very
informative to expand upon solid-state structural data
through the use of solution approaches.
In the current report, we describe the use of lysine
acetylation technology to analyze the changes in surface
accessibility that occur during Efb(-C)/C3d binding.
Moreover, we conducted a protein charge state distri-
bution analysis using electrospray ionization mass
spectrometry (ESI MS) to investigate whether lysine
acetylation induces structural changes on target pro-
teins. In addition to providing a solution perspective to
formation of this immune evasion complex, our results
have identified additional points of contact between
Efb(-C)/C3d that were not visible in the structure of the
complex. This work sets the stage for future studies into
the contribution of these interactions to complement
inhibition by Efb(-C). In addition, they lay a foundation
for the use of selective lysine labeling approaches to
monitor ligand-induced conformational changes in C3.
Experimental
Materials
Recombinant Efb, Efb-C, and C3d were prepared in a
manner identical to that used for crystallization and
structure/function studies [26]. Chymotrypsin and
glutamic-C V8 were purchased from Princeton Separa-
tions, Inc. (Adelphia, NJ). Sinapinic acid (SA) and
-cyano-4-hydroxycinnamic acid (CHCA) were pur-
chased from Waters (Milford, MA). Trifluoroacetic acid
(TFA) and mass spectrometry grade acetonitrile (AcN)
were purchased from Riedel-de Haën (Seelze, Ger-
many). All the water used in the experiments was
obtained from a Milli-Q System (Millipore, Bedford,
MA). ZipTip C18 tips were purchased from Millipore
(Bedford, MA). MS calibration standards for both the
reflectron (poly(ethylene glycol), PEG 700-4000) and
linear (insulin, cytochrome-c, hemoglobin, myoglobin,
and trypsinogen) modes were purchased from Sigma-
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Standard for LockMass (Micromass, UK) was pur-
chased from Sigma-Aldrich.
N-acetyl-hydroxysuccinimide (NHS-Ac) was synthe-
sized according to established methods [27] using com-
mercially available materials without any further pro-
cessing. N,N=-dicyclohexylcarbodiimide (7.64 g, 37.0
mmol) (Sigma-Aldrich, St. Louis, MO) was slowly
added to a stirred room-temperature solution contain-
ing glacial acetic acid (1.9 mL, 33.2 mmol) (Fisher,
Fairlawn, NJ) and N-hydroxysuccinimide (3.80 g, 33.0
mmol) (Sigma-Aldrich, St. Louis, MO) dissolved in
dichloromethane (33 mL) (Fisher, Fairlawn, NJ). A
precipitate formed and the reaction was exothermic; an
additional 20 mL dichloromethane was added. The
reaction was allowed to stir for 12 h. The mixture was
filtered through a medium porosity glass fritted filter
funnel, the solids rinsed with excess dichloromethane,
and the combined organic filtrates were concentrated
by rotary evaporation. The crude product was recrys-
tallized from ethanol; 3.1304 g of a white crystalline
solid product was obtained (60% yield). NHS-Ac was
analyzed by 1H NMR (400 MHz; (Bruker, Rheinstetten,
Germany) in CDCl3:  2.84 (s, 4H),  2.35 (s, 3H).
MALDI-TOF
All MALDI experiments were carried out using a Wa-
ters Micromass MALDI micro MX mass spectrometer
with time-of-flight (TOF) analyzer (Waters Micromass,
Milford, MA). The instrument is equipped with a N2
UV laser emitting at 337 nm, a pulsed ion extraction
source, an electrostatic reflectron of 2.3 m effective path
length, a 2 GHz 8-bit transient analog to digital con-
verter with real time peak display and fast dual micro-
channel plate detectors. All sample solutions were
mixed in a 1:1 volume ratio with a matrix solution. For
reflectron mode, the matrix solution consisted of 10
mg/mL -cyano-4-hydroxycinnamic acid in 1:1 AcN:
0.1% TFA, while 10 mg/mL sinapinic acid in 4:6 AcN:
0.1% TFA was used as the matrix solution for linear
mode. 0.8 L of each sample-matrix mixture was spot-
ted on the target plate and allowed to dry under
moderate vacuum for 1 min. The acceleration voltage
was set to 20 kV for all experiments, and typically 50
single-shot mass spectra were summed to give a com-
posite spectrum. All data were reprocessed using Wa-
ters MassLynx software. The mass scale was calibrated
externally using poly(ethylene glycol) (PEG 700-4000)
for reflectron mode and a defined peptide mixture
(insulin, cytochrome-c, hemoglobin, myoglobin, and
trypsinogen) for linear mode.
LC-MS/MS
For all LC-MS/MS studies, the LC system consisted of
an Ultimate nano HPLC system (LC Packings, Amster-
dam, The Netherlands), an ABI syringe delivery pump
(Applied Biosystems, Foster City, CA), a rheodyneinjection valve (model 7125) and 3 rheodyne switch
valves (model 7000) (Rohnert Park, CA), a C8 peptide
microtrap (Michrom, Auburn, CA), and a 50 mm Vydac
18 column (i.d. 1.0 mm, 300 Å, 5 m) from Alltech
(Deerfield, IL). The Ultimate nano HPLC system was
controlled by Ultichrom software (Dionex, Bavel, The
Netherlands). After a 30-min equilibration at 50 L/
min flow rate of the LC system with Buffer A (99.95%
water and 0.05% TFA), 0.3 nmol predigested protein
was injected into the rheodyne injection valve and
loaded onto the peptide trap at 50 L/min flow rate
(delivered by the ABI pump) for 3 min to accomplish
sample desalting. Afterwards, manipulation of the
switch valve allowed a gradient delivered by the LC
Packings system to elute the peptides from the peptide
trap onto the C18 analytical column. During the first 30
min buffer B (80% AcN, 20% water, and 0.01% TFA)
was increased from 0 to 60%, at which time buffer B was
increased to 95% in 1 min and maintained at that
percentage for another 5 min. Finally, the system was
reconditioned by decreasing buffer B to 0% in 1 min and
maintaining this condition for 30 min.
The LC system was interfaced with an ESI-MS by
PEEK tubings (i.d.  0.005 in.). All ESI-MS/MS spectra
were acquired with helium as the collision gas on a
Finnigan LCQ DUO ion trap mass spectrometer (Finni-
gan Co., San Jose, CA) equipped with a fritless electro-
spray interface under the control of the Finnigan Xcali-
bur program. The LCQ instrument was run under the
following conditions: spray needle voltage 4.5 kV,
heated capillary temperature 200 °C, mass range 200–
2000 Da in each full-MS or MS/MS scan. A three-stage
tandem MS method was used to obtain MS/MS data:
full-MS scan, zoom scan and MS/MS scan. The result-
ing tandem mass spectra were used for peptide se-
quence interpretation and database searching using the
SEQUEST program. The fragment ion mass accuracy
was specified as 0.5 Da. To identify a peptide, the
following criteria were used: (1) cross-correlation score
1 for single-charged fragments; (2) cross-correlation
score 2 for multi-charged fragments.
ESI-MS
In the charge state distribution analysis, gas-phase
protein ions were produced in the positive mode by
pneumatically assisted ESI at a flow rate of 4 L/min.
The concentration of all protein samples was 5 M. All
other instrumental conditions were identical to those
described in the MS/MS experiments.
Sample Preparation
The main procedure of sample preparation is shown
in Figure 1. In the free protein experiments, Efb(-C) or
C3d was diluted in reacting buffer (100 mM Na2CO3,
pH 8) to 7.3 M; 90 L of protein solution was mixed
with 90 L of reacting buffer to make a 180 L
mixture. The mixture was divided into two 90-L
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added to aliquot A while 10 L NHS-Ac solution (2 M
NHS-Ac in AcN diluted 10-fold in reaction buffer)
was added to aliquot B. Acetylation was allowed to
proceed for 20 min at room temperature. At this time,
300 L of quenching buffer (200 mM NH4HCO3, pH
8) was added, and each sample was incubated for 20
min further at room temperature; 10 L of each
sample was removed and acidified to pH 2. Before
subjecting the protein to linear mode MALDI-TOF
MS, the protein was desalted and concentrated by a
ZipTip according to manufacturer’s suggestions. To
the other 390 L sample, appropriate proteases (20
ng/L) were added to achieve a protein/protease
mass ratio of 50:1. Overnight digestions were per-
Figure 1. Brief scheme of experimental labelin
color) or their complex are labeled using the
temperature, the acetylation reaction is quen
proteolytic digestion. Both chymotrypsin and glu
peptide coverage maps.formed at 37 °C for chymotrypsin and 28 °C for V8.Following digestion, 10 L of peptide mixture was
desalted by ZipTip and subjected to reflectron mode
MALDI-TOF MS. The remaining peptide mixture was
injected into the LC system for the ESI-MS/MS anal-
ysis to create the peptide pool.
In experiments with the Efb(-C)/C3d protein com-
plexes, the same protocol as above was applied, except
that ESI-MS/MS analysis was omitted as the peptide
pool had already been created. All experiments were
repeated three times to ensure reproducibility and
reliability.
In the charge state study, all samples were prepared
in 200 mM NH4HCO3 to ensure a chemical environ-
ment identical to the quenching solution following
lysine acetylation (see above). The pH of each sample
ocedure. C3d (in dark color), Efb(-C) (in light
e acetylation reagent. After 20 min at room
by addition of NH4HCO3 and followed by
ic-C V8 were used to achieve the most completeg pr
lysin
ched
tamwas measured by an accurate pH meter (Denver Instru-
f Efb
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the desired value using either hydrochloric acid or
ammonium hydroxide.
Results and Discussion
N-acetyl-succinimide is an efficient acetylating reagent
and our first goal was to address if it would be a useful
tool for analysis of the Efb(-C)/C3d interaction. Opti-
mization of the reaction conditions using Efb-C and
C3d suggested that the acetylation studies were best
performed with a minimum 200:1 molar ratio of acety-
lating reagent:lysine for 20 min at room temperature.
At a sequence level, Efb and Efb-C are comprised of
20 and 13 lysine residues each. Consequently, such
extensive acetylation of reactive lysines might result in
alteration or destabilization of the protein structure or
changes in overall protein solubility. Analysis of a
protein’s charge state distribution by ESI is a commonly
used method to investigate global structural transitions
of proteins in solution [28]. Protein ions generated in the
gas phase by electrospray ionization are able to carry
multiple charges due to the presence of multiple ioniz-
able groups. Structural changes in proteins lead to
changes in both the steric accessibility as well as in the
pKa of these protic sites [29]. Since the accessible surface
area is expanded in unfolded proteins [30], a well-
folded native protein is typically found distributed
throughout lower charge states compared with its un-
folded counterpart by ESI. Optical spectroscopy meth-
ods have confirmed these results from ESI and estab-
lished that this charge state distribution is highly
sensitive to tertiary structural changes in the polypep-
tide chain [31].
To address questions of acetylation-induced struc-
Figure 2. ESI mass spectra of Efb and acetylate
8; (b) Efb at pH 5; (c) acetylated Efb at pH 8, (d)
to the corresponding charge states. Note tha
distribution as native protein at multiple pH va
state distribution analysis of Efb-C (see Supplem
reaction itself did not perturb the folding state otural changes, we monitored the charge state distribu-tion of both free and acetylated Efb and Efb-C at
multiple pH values from 8 to 3 under native conditions
by ESI mass spectrometry. Examination of the resulting
spectra for free (Figure 2a, b) and acetylated Efb (Figure
2c, d) revealed a similar distribution change of charge
states between both samples at different pH. As shown
in Figure 2a, c, the dominant center ion peak of 9
indicated that both free and acetylated Efb were well-
folded at pH 8 and that the two samples were in
conformational states indistinguishable through this
technique. Furthermore, the fact that additional charge
states became populated for both samples as the pH
grew more acidic demonstrated that this ESI method
was capable of detecting such changes when they
occurred. Similar results were obtained with the charge
state of Efb-C (see Supplemental Figure S1, which can
be found on the electronic version of this article). The
much smaller size of Efb-C compared with full-length
Efb resulted in a complete charge-state pattern. The
results show that the acetylated-Efb-C has the same
pattern as Efb-C and that it is similar to Efb (Figure 2).
The 6 is the highest peak for Efb-C followed the much
lower 7 peak. In Figure 2, the intensity of the 9 peak
is much higher than 10, which is again similar to
Efb-C’s pattern. Thus, the ESI data revealed that lysine
acetylation did not perturb the global structural integ-
rity of either Efb or Efb-C.
To gauge the efficiency of the acetylation reaction,
free Efb, Efb-C, and C3d were acetylated as described
above and analyzed by MALDI-TOF MS. The proteins
were initially monitored in linear mode, since this
allowed for measurement of the entire protein mass.
Accordingly, it was possible to determine the number
of lysine residues modified by inspection of the ob-
served mass difference between the unlabeled and
recorded at different pH values. (a) Efb at pH
ylated Efb at pH 5. Peaks are labeled according
tylated Efb displayed the same charge state
Similar results were obtained in an ESI charge
l Figure S1). This suggested that the acetylation
(-C).d Efb
acet
t ace
lues.
entalabeled protein samples. The linear-mode MALDI spec-
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Figure 3a, e, and Figure 3b, f, respectively. For example,
the mass differential between Figure 3a and b is 546 Da,
indicating that there were 13 modifications in the free
Efb-C sample (546 Da/42 Da13, where 42 Da is the
molecular weight of the acetyl group). A similar result
was seen in the case of Efb, where 19 lysines were
modified (see Figure 3e and f). The mass shift between
unlabeled and labeled C3d was also determined (data
not shown). However, unlike Efb(-C), C3d was not fully
acetylated as some lysine residues are buried in the
native structure [32]. In addition, we also observed a
mixture of C3d molecules that corresponded to variabil-
Figure 3. MALDI spectra of Efb-C (a)–(d) and Efb (e)–(h) under
linear mode. Sample identities are (a) free Efb-C without lysine
acetylation; (b) free Efb-C with lysine acetylation; (c) Efb-C/C3d
without lysine acetylation; and (d) Efb-C/C3d with lysine acety-
lation; (e) free Efb without lysine acetylation; (f) free Efb with
lysine acetylation; (g) Efb /C3d without lysine acetylation; and (h)
Efb /C3d with lysine acetylation. The mass differential between
samples A and B was 546 Da 9151-8605, indicating that 13 lysine
residues were acetylated in the free protein sample. In contrast,
the 336 Da (  8939-8603) difference between complex samples C
and D demonstrated that only 8 lysine residues were labeled. The
differential labeling between free and bound proteins is caused by
the protection of five Efb-C lysine residues in the protein complex.
The same number can be obtained from the Efb spectra (e)–(h).ity in the extent of acetyl modifications. Under linearmode, MALDI-TOF MS was not able to resolve these
populations adequately and yielded a broad peak that
precluded a precise determination of label density.
Nevertheless, the centroid value of the C3d peaks
suggested that the number of lysines modified was
about 14. In the end, Efb and Efb-C were chosen as the
major target for the protein–protein interaction study
because of the superior resolution afforded in this
approach.
We then examined whether formation of the Efb(-
C)/C3d complex might influence the acetylation profile
of Efb(-C). To address this question, both Efb and Efb-C
were incubated separately in the presence of equimolar
concentrations of C3d and subjected to acetylation
under identical experimental conditions as those de-
scribed above. Analysis of bound Efb-C revealed a mass
differential after modification of 336 Da, which corre-
sponded to labeling of 8 lysine residues (see Figure 3c
and d). These results were consistent with protection of
five lysine residues in Efb-C from acetylation when
bound to C3d. A similar mass differential was observed
in the case of Efb (see Figure 3g and h).
To investigate the identities of these five lysine
residues in detail, spatial resolution was achieved by
digestion of the labeled samples with either chymotryp-
sin or glutamic-C V8. Both of these enzymes have
different sequence selectivity, and neither requires a
substrate lysine residue for activity. Although the prod-
ucts of chymotrypsin or glutamic-C V8-catalyzed pro-
teolysis can be predicted with some certainty, we nev-
ertheless obtained empirical identification of the
resulting proteolytic peptides. To facilitate this, we
utilized MALDI-based peptide mass fingerprinting and
LC/ESI tandem MS (Table 1).
The accurate mass data provided by MALDI-TOF
analysis (within 50 ppm by the external calibration)
allowed identification of multiple chymotryptic Efb
peptides through the peptide mass fingerprinting
(PMF) method, 15 of which contained lysines (see Table
1). To further characterize these fragments, LC/ESI
tandem MS was employed. Under the helium collision-
induced dissociation (CID) mode, abundant b series
and y series ions were produced, and these resulted in
an independent identification all 15 fragments observed
in the MALDI-TOF spectrum. For example, fragment
NKPAAKTDATIKKEQKL (95–111, m/z 1884) of Efb(-C)
was selected for MS/MS analysis by the ESI. Eight out
of 16 possible b series and 10 out of 16 possible y series
ions were observed and provided unambiguous identi-
fication of the sequence. In this fashion, a 15-member
pool of chymotryptic peptides that covered 69% of the
Efb sequence was identified. To expand the peptide
coverage map of Efb, we carried out an analogous set
of experiments using V8 protease. Here, nine lysine-
containing fragments were identified by PMF (see Table
1) and these provided independent sequence coverage
of 83%. Fortuitously, this 83% of the sequence contained
much of the Efb sequence not obtained in the chymo-
trypsin analysis; only residues 29–31 and 84–87 were
y MA
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Table 1. Together, we obtained 95% sequence coverage
of Efb by integrating both proteolytic peptide maps.
With the ability to identify the proteolytic peptides
of Efb(-C) produced after chymotrypsin or V8 diges-
tion, we next analyzed the effects of C3d binding on
Efb(-C) acetylation at the peptide level (Table 1). Four
lysine-containing peptides were found to have differ-
ent acetylation levels when comparing their mass
spectra following chymotrypsin digestion of Efb(-C)
labeled in either the presence or absence of C3d. The
MALDI spectrum of one of these fragments is shown
in Figure 4a–d). Fragment NKPAAKTDA-
TIKKEQKLIQAQNL (95–117, m/z 2551) of Efb-C con-
tains five lysine residues. In the acetylation experi-
ments of free Efb-C, we observed a 210 Da mass
increase, from m/z 2551 to m/z 2761; this indicated
that all five lysine residues were labeled by acetyl
groups. However, when C3d was present we ob-
served a fragment m/z 2593, which represented a
monoacetylated adduct. That is to say, only one
lysine residue was labeled and the other four were
protected by binding to C3d. A similar change was
detected for peptide NKPAAKTDATIKKEQKL (95–
Table 1. Experimental lysine-containing fragments for Efb and
Chym
Sequencea m/z
160KQGLVK165 672
58QSRPKF69 762
73KHDYNIL79 902
64NSTPKYIKF72 1098
73KHDYNILEF81 1179
58QSRPKFNSTPKY69 1453
152QERIDNVLKQGLVK165 1640
145KVKKMVLQERIDNVL159 1813
58QSRPKFNSTPKYIKF72 1841
95NKPAAKTDATIKKEQKL111 1884
34GPREKKPVSINHNIVEY50 1980
34GPREKKPVSINHNIVEYNDGTF55 2514
89GARPQFNKPAAKTDATIKKEQKL111 2540
95NKPAAKTDATIKKEQKLIQAQNL117 2551
87EYGARPQFNKPAAKTDATIKKEQKL111 2833
Glu
Sequence m/z
144YKVKKMVLQE153 1266
109QKLIQAQNLVRE120 1440/1439
88YGARPQFNKPAAKTD102 1664
109QKLIQAQNLVREFE122 1716/1715
32GYGPREKKPVSINHNIVE49 2037
88YGARPQFNKPAAKTDATIKKE108 2334
123KTHTVSAHRKAQKAVNLVSFE143 2351
121FEKTHTVSAHRKAQKAVNLVSFE143 2627
53GTFKYQSRPKFNSTPKYIKFKHDYNILEFND83 3826
aThe peptide sequence identified in peptide pool;
bthe number of acetylated lysine residues observed in unbound protei
cthe number of acetylated lysine residues observed in bound protein b
dSamples wherein the specific peptides were observed.111), which is a part of the aforementioned NKPAAK-TDATIKKEQKLIQAQNL peptide. In both cases,
equivalent results were attained for two unique Efb
peptides that also covered residues 87–111. Differen-
tial lysine protection was not observed for any of the
remaining Efb(-C) peptides, nor was any protection
observed in peptides comprised of residues 31–93
that are unique to Efb.
In the V8-digestion experiment, we found that five
out of nine lysine-containing fragments from Efb(-C)
experienced a reduction in acetylation in the presence of
C3d (Table 1). The MALDI spectra of fragment FEKTH-
TVSAHRKAQKAVNLVSFE (121–143, m/z 2627) are
shown in Figure 4e–h. We found that this particular
peptide from Efb(-C) was fully acetylated in the absence
of C3d, and formed the [M  3Acetyl] adduct with a
corresponding mass increase to m/z 2754 from m/z 2627.
After binding to C3d, we observed a dominant [M  2
 Acetyl] adduct (m/z 2712) in the spectrum, even
though a weak [M  3  Acetyl] peak was still visible.
This change demonstrated that one of the three lysine
residues in this fragment from Efb(-C) was protected in
the presence of C3d. Again, no protection was observed
in peptides GYGPREKKPVSINHNIVE (32–49, m/z
psin
Unboundb Boundc Obsd
N/A N/A Efb-C
1 1 Efb
1 1 Efb
2 2 Efb
1 1 Efb
2 2 Efb
1 1 Efb
3 3 Efb-C
3 3 Efb
5 1 Efb-C
1,2 1,2 Efb
1,2 1,2 Efb
5 1 Efb
5 1 Efb-C
5 1 Efb
c-C
Unbound Bound Obs
3 2 Efb
1 1 Both
2 0 Efb
1 1 Both
1,2 1,2 Efb
4 0 Efb
3 2 Both
3 2 Both
4 4 Efb
MALDI-TOF MS;
LDI-TOF MS;Efb-C
otry
tami
n by2037) or GTFKYQSRPKFNSTPKYIKFKHDYNILEFND
62 CHEN ET AL. J Am Soc Mass Spectrom 2008, 19, 55–65(53–83, m/z 3826) that are comprised of residues unique
to Efb.
We used techniques analogous to those described
above to perform a reciprocal analysis that monitored
the effects of Efb(-C) binding on the acetylation of C3d
lysine residues. We observed 18 lysine-containing chy-
motryptic peptide fragments of C3d by MALDI-TOF.
These fragments were characterized by LC-ESI MS/MS
sequencing and are shown in Table 2. Two out of 18
fragments experienced a change in their acetylation
profile in response to Efb(-C) binding. We found that
Figure 4. MALDI spectra of peptide fragment N
(a)–(d) and fragment FEKTHTVSAHRKAQKAV
from samples (a) free Efb-C without lysine ac
Efb-C/C3d without lysine acetylation; and (
differential of 168 Da (210 Da  42 Da) in the fr
4 lysine residues in Efb-C were protected upon
acetylation; (f) free Efb-C with lysine acetylation
Efb-C/C3d with lysine acetylation. The mass dif
versus the protein complex indicated that a si
protected upon Efb-C/C3d binding.C3d fragment CGAVKW (1101–1106, m/z 663) wascompletely protected in the presence of Efb(-C); this
same peptide displayed an m/z of 705 Da, which corre-
sponded to the monoacetyl adduct of K1105 in the
absence of Efb(-C). For the C3d fragment ISLQEAKDI-
CEEQVNSLPGSITKAGDFL (1149–1176, m/z 3005), we
observed an adduct [M  2  Acetyl] (m/z 3089) that
indicated acetylation of both lysine residues when C3d
was labeled in the absence of Efb(-C). However, in the
presence of Efb(-C), only the monoacetyl adduct [M 1
 Acetyl] (m/z 3047) was detected. In contrast to both of
these, a third fragment from C3d, VVKVF (1082–1086,
AKTDATIKKEQKLIQAQNL (95–117, m/z 2551,
FE (120-143,m/z 2627, (e)–(h) of Efb(-C) derived
ion; (b) free Efb-C with lysine acetylation; (c)
fb-C/C3d with lysine acetylation. The mass
otein versus the protein complex indicated that
-C/C3d binding; (e) free Efb-C without lysine
Efb-C /C3d without lysine acetylation; and H)
tial of 42 Da (136 Da  84 Da) in the free protein
lysine residue in this peptide from Efb-C wasKPA
NLVS
etylat
d) E
ee pr
Efb
; (g)
feren
nglem/z 591), was not acetylated in either the absence or
n by
y MA
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residue within this fragment is buried within C3d.
Indeed, examination of the C3d crystal structure reveals
that this lysine residue is hidden within an insulated
pocket [32].
Efb forms a nanomolar-affinity complex with native
C3, and in doing so induces a conformational change
that blocks formation and deposition of C3b on acti-
vated surfaces. According to our previous studies, the
C3-inhibitory domain of Efb or Efb-C is comprised of
three canonical  helices (N-terminal 1 helix from
K106 to H125, short loop 2 helix from V127 to L139
and C-terminal 3 helix from K145 to Q161) and a
randomly coiled terminus from G162 to R165 [26]. As
depicted in Figure 5, each of the Efb-C helices donates
one or more residues that contact C3d. However, there
was no interpretable electron density for residues F94 to
K100 of Efb-C in the Efb-C/C3d co-crystal, and so this
sequence was not present in the refined model. This
raised questions as to the structure of the N terminally-
directed regions of the Efb molecule, and whether
residues in this domain made any contributions to C3d
binding. In the present work, we have used a lysine
acetylation and mass spectrometry method to charac-
terize the solvent-exposure profile of the Efb(-C)/C3d
complex. This study not only identified additional sites
of protein–protein interaction involving two lysine res-
idues invisible in the Efb-C/C3d crystal structure, but
also provided an independent assessment of the Efb-C/
C3d structure in two physical states. Our analysis
highlights the complementary nature of liquid- and
solid-phase techniques in studying protein structure
and interactions.
According to the linear MALDI data five Efb(-C) lysine
residues were protected upon binding to C3d. The loca-
Table 2. Experimental lysine-containing chymotrypsin fragment
Sequencea
1082VVKVF1086
1101CGAVKW1106
1070VKRAPSTW1077
1038GLEKRQGAL1046
1070VKRAPSTWL1078
1283QKDAPDHQEL1292
1038GLEKRQGALEL1048
1211LTTAKDKNRW1220
1028LDETEQWEKF1037
1067AAFVKRAPSTWL1078
1107LILEKQKPDGVF1118
1070VKRAPSTWLTAY1081
1134RNNNEKDMALTAF1146
1212TTAKDKNRWEDPGKQL1227
1211LTTAKDKNRWEDPGKQL1227
1212TTAKDKNRWEDPGKQLY1228
1110EKQKPDGVFQEDAPVIHQEMIGGL1133
1149ISLQEAKKDICEEQVNSLPGSITKAGDFL1176
aThe peptide sequence identified in peptide pool;
bthe number of acetylated lysine residues observed in unbound protei
cthe number of acetylated lysine residues observed in bound protein btions of these five lysines were revealed by subsequentproteomic studies. In chymotryptic fragments NKPAAK-
TDATIKKEQKL (95–111) and NKPAAKTDATIKKE-
QKLIQAQNL (95–117), four out of five lysine residues
were protected from acetylation in the presence of C3d.
Our finding that the V8-derived fragment QKLIQAQN-
LVRE (109–120) was fully acetylated independently of
C3d demonstrated that K110was the unmodified lysine in
these chymotryptic peptides. The remaining protected
lysine residue was found in fragments KTHTVSAHR-
KAQKAVNLVSFE (123–143) and FEKTHTVSAHR-
KAQKAVNLVSFE (121–143). Of these, residue K135 is the
most plausible candidate since its side-chain amine ap-
pears to participate in a salt bridge with the D1156
carboxylate of C3d in the crystal structure [26].
Our present work has identified the five Efb(-C)
lysine residues protected by C3d binding as K96, K100,
K106, K107, and K135. Two of these lysines, K96 and
K100, were invisible in the Efb-C/C3d structure. Sepa-
rately, we also identified a lysine residue within C3d,
namely K1105 of fragment CGAVKW (1101–1106), that
was protected from acetylation in the presence of Efb(-
C). Together, these results support the hypothesis that
additional contacts may form between Efb and C3d.
Correlation of the solution mapping studies presented
here with the available co-crystal structure suggests
that Efb residues 84–101 are in contact with C3d near
the vicinity of residue K1105 (see Figure 6). Given the
geometry of the Efb-C/C3d complex, we feel that the
most likely explanation for this is that the N-terminally
directed region of Efb extends downward to allow
binding of Efb residues 84–101 with the residue(s)
around K1105, or even with K1105 directly. Such a
model appears to explain not only the strong protection
from acetylation of Efb(-C) fragment NKPAAKTDA-
TIKKEQKL (95–111), but also the additional protected
C3d
/z Unboundb Boundc
591 0 0
663 1 0
944 1 1
971 1 1
057 1 1
180 1 1
213 1 1
232 2 2
324 1 1
346 1 1
386 1 1
392 1 1
523 1 1
886 3 3
000 3 3
050 3 3
662 2 2
005 2 1
MALDI-TOF MS;
LDI-TOF MS.s of
m
1
1
1
1
1
1
1
1
1
1
2
2
2
3lysine in C3d following complex formation. While the
64 CHEN ET AL. J Am Soc Mass Spectrom 2008, 19, 55–65precise role of these additional contributions remains to
be established, it is interesting to note that binding of
Efb to C3d has been shown to release additional en-
thalpy when compared with Efb-C (9.0 versus 8.5
kcal/mol; [26]). Thus, even though a portion of the
additional residues that bind C3d are found in Efb-C,
the dynamics of the truncated protein may be altered in
such a way that precludes their forming a stable inter-
face that contributes significantly to binding energy (as
mentioned above) [26].
Conclusions
By combining the data from the lysine acetylation
studies of Efb(-C), C3d, and their binary complexes, we
have provided new insight on the solvent accessibility
of the full-length Efb protein and how this changes
Figure 5. Solution contacts of Efb(-C) and C3d mapped onto the
Efb-C crystal structure. The results of differential lysine acetyla-
tion studies for free and bound Efb(-C) are superimposed on the
Efb-C crystal structure (orange ribbon); two orthogonal views are
shown and were generated by rotating in the plane of the page.
Residues K106, K110, H130, R131, K135, N138, and K148 of Efb-C
were previously identified by X-ray crystallography as contribut-
ing to formation of Efb-C/C3d; K110 was solvent accessible in
fragment QKLIQAQNLVRE (109–119), and K148 was fully acety-
lated in the fragment KVKKMVLQERIDNVL (145–159), both of
which were derived from the Efb-C/C3d complex; K110 and K148
are therefore shown in green since they do not appear to interact
strongly with C3d. Oppositely, K106 was protected in fragment
NKPAAKTDATIKKEQKLIQAQNL (95–117), and K135 was pro-
tected in the fragment FEKTHTVSAHRKAQKAVNLVSFE (121–
143) obtained from the complex. Thus, the five lysine residues that
are protected in the protein complex are shown in red: K96, K100,
K106, K107, and K135. Since K96 and K100 lie within a disordered
region of the Efb-C structure, these residues cannot be displayed;
H130, R131, and N138 are shown in purple since these side chains
do not react with NHS-Ac.upon formation of a highly specific protein–proteininteraction with C3d. The results of current analysis
have revealed the presence of additional interactions
that further our molecular level understanding of the
Efb/C3 complex beyond what was provided by X-ray
crystallography. Although the contribution of these
additional interactions is a topic of ongoing investiga-
tion, it is critical that all such sites of interaction
between these proteins are identified if we are to
completely understand the structure/function relation-
ships for this class of bacterial immune evasive mole-
cules. Since the mechanism of Efb-mediated inactiva-
tion of C3 involves the induction of conformational
change, it is entirely possible that apparently subtle
and/or transient interactions could have dramatic con-
sequences on the molecular dynamics that are known to
contribute greatly to the many complex functions of C3.
In this regard, it is worth noting that we have described
the potential for additional interactions between the 3
helix of Efb(-C) and the -chain of native C3 [26], and
suggested that these may be important to the confor-
Figure 6. Interaction sites of C3d binding to Efb(-C) as deter-
mined by differential lysine acetylation. Efb-C is drawn as in
Figure 6, while C3d is shown in ribbons colored according to
regions of peptide coverage as described in Table 2 (blue ribbon)
and uncovered regions (gray). Selected contacting residues of C3d
that bind to Efb-C according to X-ray crystallography are shown in
green. These are H1026, D1029, R1042, N1091, S1097, D1156, and
E1160; K1155 in fragment ISLQEAKDICEEQVNSLPGSITKAG-
DFL (1149–1176) was protected in Efb-C/C3d, implying that
D1156 may contact Efb-C. In addition, K1105 in fragment
CGAVKW (1101–1106) was protected from acetylation in the
complex. This suggested that portions of Efb(-C) not present in the
crystal structure model may also be contacting C3d near residue
K1105. The potential location for additional contacts invisible in
the Efb-C/C3d crystal structure is depicted by a dashed orange
line. No evidence was obtained regarding the role of R1042 in the
Efb-C/C3d complex, since K1041 in fragment GLEKRQGAL
(1038–1046) was solvent accessible in the complex. Similarly, no
further information was available for H1026, D1029, and N1091 as
no identified peptides covered this sequence, nor were there any
lysine residues in these regions.
65J Am Soc Mass Spectrom 2008, 19, 55–65 LYSINE MAPPING OF Efb/C3d INTERACTIONSmational effects of Efb(-C) binding on C3 structure. The
results we present here have established the method of
the lysine acetylation combined with proteolytic diges-
tion and mass spectrometric analysis as a valuable tool
for studying the Efb(-C)/C3 interactions in solution.
Clearly, analogous studies on the C3 complex will be
more involved than those reported here for C3d, since
native C3 contains greater than six times the residues of
C3d. However, incorporation of the higher resolution
LC-ESI-MS/MS analytical platform is likely to make
these differential-labeling approaches more practicable.
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